Research Projects & Grants

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: Investigator, Duke University, (12/2023 - 12/2024) Status: Approved

Federal

  • COG- AHOD0831: A non-randomized phase III study of response adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin's Lymphoma, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's Oncology Group (COG) - AALL0631: A Phase III study of risk directed therapy for infants with acute lymphoblastic leukemia (ALL): Randomization of highest risk infants to intensive chemotherapy +/- FLT3 inhibition (CEP-701, lestaurtinib; IND#76431; NSC#617807), Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children’s Oncology Group (COG) protocol AOST06B1 – collecting and banking osteosarcoma specimens, Role: Investigator, Children Oncology Group, (05/2023 - 05/2024) Status: Completed
  • COG-ACNS0332: A study evaluating the efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG - ACCRN07: Protocol for the Enrollment on the Official Registry, the Childhood Cancer Research Network (CCRN)., Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG – ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: Investigator, Children Oncology Group, (03/2023 - 02/2024) Status: Completed
  • COG: AREN0533 - Treatment of newly diagnosed higher risk favorable histology Wilms tumors, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG: AALL0434 - Intensified methotrexate, nelarabine (compound 506U78; IND# 52611) and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-Cell Lymphoblastic Lymphoma, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG- AREN03B2 - renal tumors classification, biology and banking study, Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG-ACNS0331 - A study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18.00 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a Phase III double randomized trial, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG - ANBL0032 - Phase III randomized study of Chimeric antibody 14.18 (Ch14.18) in high risk Neuroblastoma following Myeloablative Therapy and autologous stem cell rescue, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG - AALL03B1 - Classification of Acute Lymphoblastic Leukemia consent for collection of additional bone marrow, Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients, Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (07/2023 - 07/2024) Status: Approved
  • COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (04/2024 - 04/2025) Status: Approved
  • COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma, Role: Investigator, Children Oncology Group, (03/2023 - 03/2024) Status: Completed
  • COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome, Role: Investigator, Children Oncology Group, (10/2023 - 10/2024) Status: Approved
  • COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors, Role: Investigator, Children Oncology Group, (09/2023 - 09/2024) Status: Approved
  • COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study, Role: Investigator, Children Oncology Group, (09/2023 - 09/2024) Status: Approved
  • COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: Investigator, Children Oncology Group, (03/2024 - 03/2025) Status: Approved
  • COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG-ANBL 1232:Utilizing response and biology based risk factors to guide therapy in patients with non-high risk neuroblastoma, Role: Investigator, Children Oncology Group, (05/2023 - 05/2024) Status: Approved
  • COG - ANHL12P1: A randomized phase 2 trial of Brentuximab Vedotin or Crizotinib in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL), Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's Oncology Group (COG) - AAML08B1: biology study of Transient Myeloproliferative Disorder (TMD) in children with Down Syndrome (DS), Role: Investigator, Children Oncology Group, (05/2023 - 05/2024) Status: Completed
  • COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy), Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • Children's oncology group (COG)-AALL08B1: Classification of newly diagnosed acute lymphoblastic leukemia (ALL), Role: Investigator, Children Oncology Group, (10/2023 - 10/2024) Status: Completed
  • Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol, Role: Investigator, Children Oncology Group, (12/2023 - 12/2024) Status: Approved
  • COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children < 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate, Role: Investigator, Children Oncology Group, (02/2024 - 02/2025) Status: Approved
  • COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000, Role: Investigator, Children Oncology Group, (04/2024 - 04/2025) Status: Approved

For Profit Organization

  • CCG D9902 A group wide protocol for collecting and banking pediatric cancer research specimens. An intergroup rhabdomyosarcoma study group protocol., Role: Investigator, Children Cancer Group, (05/2023 - 05/2024) Status: Completed

Foreign

  • Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease, Role: Investigator, Canadian Institutes of Health Research, (09/2023 - 09/2024) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (10/2023 - 10/2024) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (07/2023 - 07/2024) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (07/2023 - 07/2024) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: Investigator, National Marrow Donor Program, (09/2023 - 09/2024) Status: Approved